Acute lymphoblastic leukemia.

The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease, and supportive care considerations. It is recommended that patients be treated at specialized centers with expertise in the management of ALL.

[1]  H. Sather,et al.  Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. , 2012, The Lancet. Oncology.

[2]  Maria Grazia Valsecchi,et al.  Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Kantarjian,et al.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet Oncology.

[4]  M. Schrappe,et al.  Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapy.

[6]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[7]  Z. Estrov,et al.  The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M Feychting,et al.  A pooled analysis of magnetic fields and childhood leukaemia , 2000, British Journal of Cancer.

[9]  A. Cherry,et al.  Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. , 2005, Blood.

[10]  Ya-Zhen Qin,et al.  Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia , 2012, Journal of Hematology & Oncology.

[11]  D. Boggs.  Hematopoietic Stem Cell Theory in Relation to Possible Lymphoblastic Conversion of Chronic Myeloid Leukemia , 2005 .

[12]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[13]  J. Rowley.  Chromosomes in leukemia and lymphoma. , 1978, Seminars in hematology.

[14]  C. Pui.  Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia , 2015, Frontiers of Medicine.

[15]  A. Taylor,et al.  Leukemia and lymphoma in ataxia telangiectasia. , 1996, Blood.

[16]  H. Kantarjian,et al.  Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia , 2006, Cancer.

[17]  Y. Ikeda,et al.  Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome‐positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid , 2002, British journal of haematology.

[18]  Kevin K Dobbin,et al.  Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. , 2010, Blood.

[19]  C. Pui,et al.  A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL) , 2011 .

[20]  S. Bertolone,et al.  Acute psychosis complicating induction therapy for acute lymphoblastic leukemia. , 1983, The Journal of pediatrics.

[21]  R. Foà,et al.  Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.

[22]  M. Tormo,et al.  Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group , 2010, Haematologica.

[23]  J. Hernández-Rivas,et al.  Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. , 2005, Haematologica.

[24]  J. Aster,et al.  A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Lilleyman,et al.  Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. , 1993, Archives of disease in childhood.

[26]  F. Behm,et al.  Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. , 2002, Blood.

[27]  M. Andreeff,et al.  Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Tei,et al.  Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions , 2008, International journal of hematology.

[29]  Elaine Coustan-Smith,et al.  New markers for minimal residual disease detection in acute lymphoblastic leukemia. , 2011, Blood.

[30]  H. Kantarjian,et al.  The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia , 1997, Leukemia.

[31]  D. Campana,et al.  Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. , 2010, Blood.

[32]  T. Lipp,et al.  Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. , 2002, Blood.

[33]  Elaine Coustan-Smith,et al.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.

[34]  C. Stiller,et al.  Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. , 1994, British Journal of Cancer.

[35]  James Allan,et al.  Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk , 2010, Nature Genetics.

[36]  W. Benedict,et al.  Correlation between prognosis and bone marrow chromosomal patterns in children with acute nonlymphocytic leukemia: similarities and differences compared to adults. , 1979, Blood.

[37]  M. Loh,et al.  Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse , 2013, Nature Genetics.

[38]  M. Béné,et al.  Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. , 2004, Blood.

[39]  N. Heerema,et al.  Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Pui,et al.  Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2000, The New England journal of medicine.

[41]  C. Bloomfield,et al.  Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia , 2013, Cancer.

[42]  M. Loh,et al.  Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  T. Lebien,et al.  Origin of chronic myelocytic leukemia in a precursor of pre-B lymphocytes. , 1979, The New England journal of medicine.

[44]  W. Stock.  Adolescents and young adults with acute lymphoblastic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.

[45]  Takashi Akasaka,et al.  Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.

[46]  J. Bourhis,et al.  Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. , 2002, Blood.

[47]  B. Summersgill,et al.  PHILADELPHIA-POSITIVE BLAST CRISIS MASQUERADING AS ACUTE LYMPHOBLASTIC LEUKÆMIA IN CHILDREN , 1976, The Lancet.

[48]  M. Konopleva,et al.  The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience , 2014, Leukemia.

[49]  R. Arceci,et al.  Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Esteve,et al.  Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial , 2010, Haematologica.

[51]  J. Downing,et al.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.

[52]  J. Chessells.  Acute lymphoblastic leukemia. , 1982, Seminars in hematology.

[53]  J. Lilleyman,et al.  Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  T. Kalina,et al.  Acute lymphoblastic leukemia incidence during socioeconomic transition: selective increase in children from 1 to 4 years , 2002, Leukemia.

[55]  J. Whang‐Peng,et al.  Cytogenetic studies in acute lymphocytic leukemia: special emphasis in long-term survival. , 1976, Medical and pediatric oncology.

[56]  M. Relling,et al.  Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients , 2003, Leukemia.

[57]  M. Relling,et al.  Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. , 2010, Blood.

[58]  Gamal Abdul Hamid,et al.  Classification of acute leukemia. , 2011, Annals of internal medicine.

[59]  H. Brenner,et al.  Survival of Adults with Acute Lymphoblastic Leukemia in Germany and the United States , 2014, PloS one.

[60]  H. Gschaidmeier,et al.  A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphobla , 2003, Annals of Hematology.

[61]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  J. Tchinda,et al.  An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome , 2014, Leukemia.

[63]  J. Neglia,et al.  A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. , 2002, Blood.

[64]  E. Thiel,et al.  Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. , 1984, Blood.

[65]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[66]  M. Konopleva,et al.  Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) , 2014, Cancer.

[67]  H. Dombret,et al.  Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[68]  S. Mustjoki,et al.  Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. , 2008, Blood.

[69]  J. Whitlock.  Down syndrome and acute lymphoblastic leukaemia , 2006, British journal of haematology.

[70]  C. Pui,et al.  The eighth international childhood acute lymphoblastic leukemia workshop (‘Ponte di Legno meeting’) report: Vienna, Austria, April 27–28, 2005 , 2006, Leukemia.

[71]  Rocco Piazza,et al.  Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  M. Tallman,et al.  In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.

[73]  S. Sallan,et al.  Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: clinical results. , 1978, Blood.

[74]  P. Neiman,et al.  Marrow transplantation for acute nonlymphoblastic leukemia in first remission. , 1979, The New England journal of medicine.

[75]  C. Bloomfield,et al.  What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. , 2008, Blood.

[76]  F. Behm,et al.  Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII , 1997, Leukemia.

[77]  A. Ferrando,et al.  T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). , 2009, Blood.

[78]  J. Beyene,et al.  Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis , 2011, Leukemia.

[79]  M. Muckenthaler,et al.  Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. , 2006, Blood.

[80]  I. Flinn,et al.  Ponatinib in refractory Philadelphia chromosome-positive leukemias. , 2012, The New England journal of medicine.

[81]  P. Dreger,et al.  Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia , 2013, Leukemia.

[82]  U. Dührsen,et al.  Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL) , 2007, Cancer.

[83]  T. Ito,et al.  Successful prevention of hematological relapse for a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation by donor leukocyte infusion , 1997, Bone Marrow Transplantation.

[84]  G. Gustafsson,et al.  Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden , 2006, Cancer.

[85]  E. Gehan,et al.  Prognostic factors in acute leukemia. , 1976, Seminars in oncology.

[86]  W. Woods,et al.  The occurrence of leukemia in patients with the Shwachman syndrome. , 1981, The Journal of pediatrics.

[87]  A. Pession,et al.  Clofarabine, cyclophosphamide and etoposide as single‐course re‐induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia , 2009, British journal of haematology.

[88]  A. Angiolillo,et al.  A phase II study of Campath‐1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report , 2009, Pediatric blood & cancer.

[89]  P. Carbone,et al.  THE DISTRIBUTION OF THE PHILADELPHIA CHROMOSOME IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA. , 1963, Blood.

[90]  J. Burchenal,et al.  Treatment of acute lymphoblastic leukemia. , 1972, Annual review of medicine.

[91]  J. Rowley,et al.  Banding studies of chromosomal abnormalities in patients with acute lymphocytic leukemia. , 1979, Cancer research.

[92]  E. Thiel,et al.  Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. , 2014, Blood.

[93]  Simona Soverini,et al.  BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. , 2011, Blood.

[94]  S. Armstrong,et al.  Molecular genetics of acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  R. Herrmann,et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.

[96]  D. Fabbro,et al.  Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia , 2004, Nature Genetics.

[97]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.

[98]  H. Kantarjian,et al.  Central nervous system relapse in adults with acute lymphoblastic leukemia , 2002, Cancer.

[99]  H. Sather,et al.  Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  H. Kantarjian,et al.  First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. , 2010, Blood.

[101]  P. Philip,et al.  Philadelphia chromosome in acute lymphocytic leukaemia , 2009 .

[102]  Y. Ishigatsubo,et al.  Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion , 2011, Leukemia & lymphoma.

[103]  W. Hofmann,et al.  Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[104]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[105]  M. Schrappe,et al.  ACUTE LYMPHOBLASTIC LEUKEMIA AND KLINEFELTER SYNDROME IN CHILDREN: Two Cases and Review of the Literature , 2004, Pediatric hematology and oncology.

[106]  C. Pui.  Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. , 2006, Hematology. American Society of Hematology. Education Program.

[107]  C. Pui,et al.  Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  D. Campana,et al.  Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real‐time PCR , 2005, British journal of haematology.

[109]  H. Kantarjian,et al.  Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors , 2008, Cancer.

[110]  H. Sather,et al.  Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  W. Crist,et al.  Lymphoblastic conversion in chronic myelogenous leukemia. , 1978, Pediatrics.

[112]  A. Bleyer,et al.  Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel , 2011, Leukemia & lymphoma.

[113]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[114]  M. Baccarani,et al.  Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia , 2006, Clinical Cancer Research.

[115]  C. Heavey,et al.  Terminal transferase expression in the differential diagnosis of acute leukemias. Eastern Cooperative Oncology Group. , 1996, Leukemia & lymphoma.

[116]  P. Sonneveld,et al.  Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands , 2004, Leukemia.

[117]  R. Larson,et al.  A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. , 1995, Blood.

[118]  G. Harrison,et al.  Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X , 1997, British journal of haematology.

[119]  A. Tsiatis,et al.  High‐dose dexamethasone for refractory or relapsing multiple myeloma , 1991, American journal of hematology.

[120]  H. Kantarjian,et al.  Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL) , 2012 .

[121]  R. Larson,et al.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[122]  H. Macdonald,et al.  Notch signaling in the immune system. , 2010, Immunity.

[123]  T. Naoe,et al.  High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  T. A. Lister,et al.  The effect of food on the oral administration of 6-mercaptopurine , 2004, Cancer Chemotherapy and Pharmacology.

[125]  Jinny Park,et al.  Nilotinib Combined With Multi-Agent Chemotherapy For Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Final Results Of Prospective Multicenter Phase 2 Study , 2013 .

[126]  B. Löwenberg,et al.  Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. , 2001, Blood.

[127]  F. Reyes,et al.  The Blast Crisis of Chronic Granulocytic Leukaemia: Megakaryoblastic Nature of Cells as Revealed by the Presence of Platelet‐Peroxidase—A Cytochemical Ultrastructural Study , 1978, British journal of haematology.

[128]  M. Palmer,et al.  SEX AND PROGNOSIS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKÆMIA , 1978, The Lancet.

[129]  R. Williams,et al.  Shwachman's syndrome and acute lymphoblastic leukaemia. , 1978, British medical journal.

[130]  H. Kantarjian,et al.  Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia , 2004, Cancer.

[131]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[132]  Michael C. Rusch,et al.  Genomic Characterization and Experimental Modeling Of BCR-ABL1 -Like Acute Lymphoblastic Leukemia , 2013 .

[133]  H. Dombret,et al.  Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia , 2010, Haematologica.

[134]  M. Tallman,et al.  Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. , 2009, Blood.

[135]  D. Baltimore,et al.  Terminal deoxynucleotidyl transferase in the diagnosis of leukemia and malignant lymphoma. , 1978, The American journal of medicine.

[136]  H. Gadner,et al.  Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. , 2000, Blood.

[137]  J. Downing,et al.  Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia , 2009, Leukemia.

[138]  Michael N Dworzak,et al.  Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.

[139]  Ryan D. Morin,et al.  Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.

[140]  O. Eden,et al.  Acute lymphoblastic leukemia and Klinefelter's syndrome. , 1992, Pediatric Hematology & Oncology.

[141]  Paul W. H. I. Parren,et al.  Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX1 , 2009, The Journal of Immunology.

[142]  A. Delannoy,et al.  A report from the LALA-94 and LALA-SA groups on hypodiploidy with 30 to 39 chromosomes and near-triploidy: 2 possible expressions of a sole entity conferring poor prognosis in adult acute lymphoblastic leukemia (ALL). , 2004, Blood.

[143]  S. Richards,et al.  Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. , 2003, Blood.

[144]  J. Gerss,et al.  Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. , 2011, Blood.

[145]  M. Baccarani,et al.  Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[147]  Lee G Luna,et al.  Manual of histologic staining methods of the Armed forces institute of pathology , 1968 .

[148]  E. Thiel,et al.  Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. , 2012, Blood.

[149]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[150]  H. Kantarjian,et al.  Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. , 2009, Blood.

[151]  E. Thiel,et al.  Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. , 2008, Blood.

[152]  J. Lipton,et al.  Isolated Central Nervous System Relapse in Lymphoid Blast Crisis Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Patients on Imatinib Therapy , 2004, Leukemia & lymphoma.

[153]  R. Collins,et al.  Donor leukocyte infusions in acute lymphocytic leukemia , 2000, Bone Marrow Transplantation.

[154]  A. Bleyer,et al.  Delays in cancer diagnosis in underinsured young adults and older adolescents. , 2007, The oncologist.

[155]  M. Schell,et al.  Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. , 1987, The New England journal of medicine.

[156]  J. Kawedia,et al.  Asparaginase in acute lymphoblastic leukemia. , 2014, Clinical lymphoma, myeloma & leukemia.

[157]  J. Cayuela,et al.  Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome – positive acute lymphoblastic leukemia : results of the GRAAPH-2003 study , 2006 .

[158]  L. Kinlen.  Infections and immune factors in cancer: the role of epidemiology , 2004, Oncogene.

[159]  Z. Estrov,et al.  AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells , 2005, Cancer.

[160]  L. Foroni,et al.  Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  M. Tallman,et al.  Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. , 2005, Blood.

[162]  J. Fiet,et al.  Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[163]  J. Craig,et al.  Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. , 1991, Leukemia.

[164]  H. Dombret,et al.  Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. , 2007, Leukemia research.

[165]  M. Greaves.  Infection, immune responses and the aetiology of childhood leukaemia , 2006, Nature Reviews Cancer.

[166]  C. Pui,et al.  Adult acute lymphoblastic leukemia , 2010, Cancer.

[167]  W. Jędrzejczak,et al.  Status of minimal residual disease after induction predicts outcome in both standard and high‐risk Ph‐negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4‐2002 MRD Study , 2008, British journal of haematology.

[168]  C. Pui,et al.  Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements , 2003, Leukemia.

[169]  J. V. van Dongen,et al.  Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. , 2011, Blood.

[170]  M. Zhou,et al.  Incidence and clinical significance of CDKN2/MTS1/P16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia. , 1997, Pediatric hematology and oncology.

[171]  H. Dombret,et al.  NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. , 2009, Blood.

[172]  M. Relling,et al.  Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  J. Nachman.  Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia , 2005, British journal of haematology.

[174]  K. Sakamoto,et al.  Topics in pediatric leukemia--acute lymphoblastic leukemia. , 2005, MedGenMed : Medscape general medicine.

[175]  R. Larson,et al.  Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. , 2007, Blood.

[176]  A. Denman,et al.  Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. , 1978, The Journal of clinical investigation.

[177]  C. Mullighan.  Genomic characterization of childhood acute lymphoblastic leukemia. , 2013, Seminars in hematology.

[178]  J. Whelan,et al.  Recruitment of adolescents and young adults to cancer clinical trials--international comparisons, barriers, and implications. , 2010, Seminars in oncology.

[179]  A. Pistorio,et al.  Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients , 2012, Leukemia & lymphoma.

[180]  R. Barr,et al.  Preliminary evidence for the common origin of a lympho-myeloid complex in man. , 1978, Acta haematologica.

[181]  W. Evans,et al.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. , 1991, The Journal of pediatrics.

[182]  R. Good,et al.  B and T lymphocytes in primary immunodeficiency disease in man. , 1973, The Journal of clinical investigation.

[183]  H. Dombret,et al.  Clofarabine Combinations in Adults with Refractory/Relapsed Acute Lymphoblastic Leukemia (ALL): A GRAALL Report , 2011 .

[184]  M. Devidas,et al.  Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. , 2005, Blood.

[185]  H. Kantarjian,et al.  Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia , 2013 .

[186]  R. Pieters,et al.  Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 , 2010, Leukemia.

[187]  L. Staudt,et al.  Oncogenic mechanisms in Burkitt lymphoma. , 2014, Cold Spring Harbor perspectives in medicine.

[188]  P. Fialkow.  The origin and development of human tumors studied with cell markers. , 1974, The New England journal of medicine.

[189]  M. Greaves,et al.  Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia , 2004, Oncogene.

[190]  Erratum for Seibel et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111:2548-2555. , 2008, Blood.

[191]  E. Papaemmanuil,et al.  Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia , 2009, Nature Genetics.

[192]  D. J. King,et al.  Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia , 1999, British journal of haematology.

[193]  L. Damon,et al.  Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[194]  S. Richards,et al.  Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 , 2010, British journal of haematology.

[195]  E. Passarge.  Bloom's syndrome: the German experience. , 1991, Annales de genetique.

[196]  E. Forman,et al.  Ph1-positive childhood leukemias: spectrum of lymphoid-myeloid expressions. , 1977, Blood.

[197]  J. Szer,et al.  The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. , 2010, Blood.

[198]  Ching-Hon Pui,et al.  Germline genomic variants associated with childhood acute lymphoblastic leukemia , 2009, Nature Genetics.

[199]  Scott E. Smith,et al.  High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  M. Greaves,et al.  Membrane marker and cell separation studies in Ph1-positive leukemia. , 1978, Blood.

[201]  H. Hasle.  Pattern of malignant disorders in individuals with Down's syndrome. , 2001, The Lancet. Oncology.

[202]  D. Neuberg,et al.  Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia , 2010, Pediatric blood & cancer.

[203]  T. Naoe,et al.  Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high‐risk acute lymphoblastic leukemia , 2006, Cancer.

[204]  P. Nilsson,et al.  Prognostic implications of chromosome analysis in acute non-lymphocytic leukemia , 1977 .

[205]  L. Robison,et al.  Assessment of the interrelationship of prognostic factors in childhood acute lymphoblastic leukemia: A report from Childrens Cancer Study Group , 1980 .

[206]  H. Kantarjian,et al.  Outcome of adults with acute lymphocytic leukemia after second salvage therapy , 2008, Cancer.

[207]  G. Garcia-Manero,et al.  Activity of alemtuzumab in patients with CD52‐positive acute leukemia , 2006, Cancer.

[208]  A. Baruchel,et al.  Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE) , 2000, British Journal of Cancer.

[209]  R. Brynes,et al.  Bone marrow aspiration and trephine biopsy. An approach to a thorough study. , 1978, American journal of clinical pathology.

[210]  D. Hoelzer,et al.  Modern therapy of acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[211]  D. Campana,et al.  Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia , 2004, Leukemia.

[212]  F. Huguet.  [Adult acute lymphoblastic leukemia]. , 2011, La Revue du praticien.

[213]  J. Baars,et al.  Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. , 2009, Blood.

[214]  H. Dombret,et al.  Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[215]  M. Perales,et al.  Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors , 2014, Haematologica.

[216]  J. V. van Dongen,et al.  Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. , 2010, Blood.

[217]  D. Teachey,et al.  T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL , 2013 .

[218]  C. Sebban,et al.  Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. , 2000, Hematology/oncology clinics of North America.

[219]  N. Heerema,et al.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. , 2006, Blood.

[220]  J. Kersey,et al.  Prognostic significance of surface marker analysis in childhood non‐hodgkin's lymphoproliferative malignancies , 1976, American journal of hematology.

[221]  H. Dombret,et al.  Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[222]  M. Tormo,et al.  Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[223]  R. Fanin,et al.  Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. , 2009, Leukemia research.

[224]  H. Kantarjian,et al.  Clofarabine in leukemia , 2010, Expert review of hematology.

[225]  P. H. Fitzgerald,et al.  Karyotope and survival in human acute leukemia. , 1976, Journal of the National Cancer Institute.

[226]  P. Jacobs,et al.  Cytogenetic studies on bone-marrow in chronic myeloid leukaemia. , 1963, Lancet.

[227]  J. Román,et al.  MYELOPEROXIDASE GENE EXPRESSION IN ACUTE LYMPHOBLASTIC LEUKAEMIA , 1997, British journal of haematology.

[228]  D. Scheinberg,et al.  A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia , 2002, Cancer.

[229]  L. Foroni,et al.  Analysis of ETV6/AML1 abnormalities in acute lymphoblastic leukaemia: incidence, alternative spliced forms and minimal residual disease value , 2000, British journal of haematology.

[230]  H. Einsele,et al.  Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. , 2012, Blood.

[231]  L. Vidal,et al.  Management of Adult Patients with Acute Lymphoblastic Leukemia in First Complete Remission: Systematic Review and Meta-Analysis. , 2009 .

[232]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[233]  H. Kantarjian,et al.  Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) , 2008 .

[234]  R. Foà,et al.  Gruppo Italiano Malattie Ematologiche dell ' Adulto ( GIMEMA ) acute lymphoblastic leukemia without additional chemotherapy : results survival in elderly Philadelphia chromosome – positive patients with Imatinib plus steroids induces complete remissions and prolonged , 2007 .

[235]  T. Brümmendorf,et al.  Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. , 2012, Blood.

[236]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[237]  G. Gatta,et al.  Adult acute lymphoblastic leukaemia. , 2004, Critical reviews in oncology/hematology.

[238]  R. Aguiar,et al.  TEL‐AML1 fusion in acute lymphoblastic leukaemia of adults , 1996, British journal of haematology.

[239]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[240]  H. Einsele,et al.  Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial , 2011 .

[241]  P. Kearns,et al.  Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia , 2011, British journal of haematology.

[242]  H. Kantarjian,et al.  Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. , 2003, Blood.

[243]  D. Blaise,et al.  Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison , 2009, Leukemia.

[244]  D. Baltimore,et al.  Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia: a co-operative study. , 1978, The New England journal of medicine.

[245]  L. J,et al.  Rearrangement of the MLL Gene Confers a Poor Prognosis in Childhood Acute Lymphoblastic Leukemia , Regardless of Presenting Age , 2002 .

[246]  C. Pui,et al.  Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. , 2007, Blood.

[247]  S. Richards,et al.  Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia , 2004, British journal of haematology.

[248]  M. Kizaki,et al.  TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-1 gene expression. , 2004, Molecular cancer research : MCR.

[249]  E. Thiel,et al.  FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors , 2013, PloS one.

[250]  D. Campana,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse , 2004, Leukemia.

[251]  Michel Sadelain,et al.  Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy , 2009, Journal of immunotherapy.

[252]  C. Bloomfield,et al.  The philadelphia chromosome in acute leukemia , 1978, Virchows Archiv. B, Cell pathology.

[253]  D. Steensma.  Oddballs: acute leukemias of mixed phenotype and ambiguous origin. , 2011, Hematology/oncology clinics of North America.

[254]  S. Bohlander,et al.  Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. , 2013, Blood.

[255]  C. Bloomfield,et al.  Lymphocytes bearing receptors for both sheep erythrocytes and complement in patients with neoplastic and non-neoplastic diseases. , 1977, Clinical immunology and immunopathology.

[256]  B. Kennedy,et al.  Chronic myelogenous leukemia presenting in blastic crisis , 1972, Cancer.

[257]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[258]  M. Verneris,et al.  Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome‐positive acute lymphoblastic leukemia (ALL) , 2009, Pediatric blood & cancer.

[259]  D. Grant,et al.  Effect of allopurinol on caffeine disposition in man. , 1986, British journal of clinical pharmacology.

[260]  Cheng Cheng,et al.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. , 2009, The Lancet. Oncology.

[261]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[262]  M. Schrappe,et al.  Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[263]  Gamal Abdul Hamid.  1 Classification of Acute Leukemia , 2012 .

[264]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[265]  H. Kantarjian,et al.  Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia , 2009, Cancer.

[266]  A. Rausen,et al.  PHILADELPHIA CHROMOSOME IN ACUTE LYMPHATIC LEUKÆMIA OF CHILDHOOD , 1977, The Lancet.

[267]  M. Kneba,et al.  Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. , 2007, Blood.

[268]  H. Gundacker,et al.  Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia , 2010, British journal of haematology.

[269]  W. Hiddemann,et al.  Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. , 2000, Blood.

[270]  R. Pieters,et al.  Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: the state of the art. , 1994, Medical and pediatric oncology.

[271]  S. de Vos,et al.  Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. , 2002, Blood.

[272]  M. Greaves,et al.  Leukemia in twins: lessons in natural history. , 2003, Blood.

[273]  C. Pui,et al.  L‐asparaginase treatment in acute lymphoblastic leukemia , 2011, Cancer.

[274]  F. Guilhot,et al.  Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia , 2009, Pediatric blood & cancer.

[275]  T. Barbui,et al.  Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). , 2009, Blood.

[276]  H. Kantarjian,et al.  Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. , 2011, Clinical lymphoma, myeloma & leukemia.

[277]  T. Enver,et al.  Initiating and Cancer-Propagating Cells in TEL-AML1-Associated Childhood Leukemia , 2008, Science.

[278]  A. Gürgey,et al.  Acute lymphoblastic leukemia associated with Klinefelter syndrome. , 1994, Pediatric hematology and oncology.

[279]  C. Pui,et al.  Central nervous system disease in hematologic malignancies: historical perspective and practical applications. , 2009, Seminars in oncology.

[280]  J. McElnay,et al.  Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. , 2008, British journal of clinical pharmacology.

[281]  Susan J. Lindemulder,et al.  Successful Intermittent Prophylaxis With Trimethoprim/Sulfamethoxazole 2 Days per Week for Pneumocystis carinii (jiroveci) Pneumonia in Pediatric Oncology Patients , 2007, Pediatrics.

[282]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[283]  J. Downing,et al.  Improved prognosis for older adolescents with acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[284]  J. Radich,et al.  Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. , 2007, Blood.

[285]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[286]  M. Baccarani,et al.  Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. , 2007, Haematologica.

[287]  Takashi Akasaka,et al.  Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. , 2010, Blood.

[288]  T. Clackson,et al.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. , 2013, The New England journal of medicine.

[289]  J. Shuster,et al.  Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906 , 2011, Pediatric blood & cancer.

[290]  E. Thiel,et al.  CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). , 2005, Blood.

[291]  Steven M Kornblau,et al.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.

[292]  T. Caspersson,et al.  Identification of human chromosomes by DNA-binding fluorescent agents , 2004, Chromosoma.

[293]  P. D. Dal Cin,et al.  Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[294]  K. Yan,et al.  Magnetic fields exposure and childhood leukemia risk: a meta-analysis based on 11,699 cases and 13,194 controls. , 2014, Leukemia research.

[295]  W. Evans,et al.  Disposition of antineoplastic agents in the very young child. , 1992, The British journal of cancer. Supplement.

[296]  Ganser,et al.  Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. , 1988, Blood.

[297]  C. Pui,et al.  Thiopurine methyltransferase activity in American white subjects and black subjects , 1994, Clinical pharmacology and therapeutics.

[298]  A. Hüttmann,et al.  High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. , 2011, Blood.

[299]  M. Territo,et al.  Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia , 1993, American journal of hematology.

[300]  R. Pazdur,et al.  FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. , 2008, The oncologist.

[301]  Dario Campana,et al.  Minimal residual disease in acute lymphoblastic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.

[302]  M. Labopin,et al.  Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation , 2014, Bone Marrow Transplantation.

[303]  B K Tang,et al.  Variability in caffeine metabolism , 1983, Clinical pharmacology and therapeutics.

[304]  S. Richards,et al.  Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial , 2005, British journal of haematology.

[305]  M. Tallman,et al.  Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. , 2006, Blood.

[306]  R. Foà,et al.  E2A–PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features , 2003, British journal of haematology.

[307]  Cheng Cheng,et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.

[308]  M. Loh,et al.  Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[309]  T. Lister,et al.  Relation of “lymphoid” phenotype and response to chemotherapy incorporating vincristine‐prednisolone in the acute phase of Ph1 positive leukemia , 1979, Cancer.

[310]  J. Radich,et al.  SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia , 2014, British journal of haematology.

[311]  L. Robison,et al.  Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia , 2014, Cancer.

[312]  R. Bassan,et al.  Current and future management of Ph/BCR-ABL positive ALL , 2014, Expert review of anticancer therapy.

[313]  G. Fabbri,et al.  Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk’ acute lymphoblastic leukemia , 2008, Leukemia.

[314]  C. Li,et al.  ACID PHOSPHATASE ISOENZYME IN HUMAN LEUKOCYTES IN NORMAL AND PATHOLOGIC CONDITIONS , 1970, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[315]  J. Cayuela,et al.  Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[316]  W. Hofmann,et al.  Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. , 2003, Blood.

[317]  M. Tallman,et al.  UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. , 2014, Blood.

[318]  A. Levis,et al.  Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[319]  K. Neville,et al.  Successful Treatment of Fanconi Anemia and T-Cell Acute Lymphoblastic Leukemia , 2012, Case reports in hematology.

[320]  F. Behm,et al.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.

[321]  H. Kantarjian,et al.  Anthracycline dose intensification in adult acute lymphoblastic leukemia , 2010, Cancer.

[322]  A. Moorman,et al.  A population-based cytogenetic study of adults with acute lymphoblastic leukemia. , 2010, Blood.

[323]  Christian Urban,et al.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. , 2007, Blood.

[324]  L. Kaplow.  SIMPLIFIED MYELOPEROXIDASE STAIN USING BENZIDINE DIHYDROCHLORIDE. , 1965, Blood.

[325]  M. Andreeff,et al.  Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[326]  W. Młynarski,et al.  The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparations , 2009, Clinical and Experimental Medicine.

[327]  E. Domany,et al.  Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. , 2010, Blood.

[328]  Rajesh Chopra,et al.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.

[329]  A. Hagemeijer,et al.  Bone Marrow Karyotypes of Children with Nonlymphocytic Leukemia , 1979, Pediatric Research.

[330]  J. Kurtzberg,et al.  Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[331]  J. Radich,et al.  Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. , 2007, Blood.

[332]  C. Bloomfield,et al.  Prognostic significance of the Philadelphia chromosome in acute lymphocytic leukemia , 1980 .

[333]  P. Kebriaei,et al.  The Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Therapy of Patients with Acute Lymphoblastic Leukemia , 2012, Current Hematologic Malignancy Reports.

[334]  Hans Clevers,et al.  Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells , 2005, Nature.

[335]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[336]  J. Cayuela,et al.  Is Less Chemotherapy Detrimental in Adults with Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with High-Dose Imatinib? Results of the Prospective Randomized Graaph-2005 Study , 2012 .

[337]  Sante Tura,et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[338]  T. Naoe,et al.  Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. , 2004, Blood.

[339]  N. Heerema,et al.  Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2003, Blood.

[340]  E. Thiel,et al.  Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.

[341]  T. Naoe,et al.  Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. , 2006 .

[342]  O. Haas,et al.  Relapse of Philadelphia chromosome positive acute lymphoblastic leukaemia after marrow transplantation: sustained molecular remission after early and dose‐escalating infusion of donor leucocytes , 1997, British journal of haematology.

[343]  M. Loh,et al.  Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2012, Blood.

[344]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[345]  M. Relling,et al.  Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[346]  Terry L. Smith,et al.  Primary refractory and relapsed adult acute lymphoblastic leukemia , 1999, Cancer.

[347]  M. Loh,et al.  Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). , 2007, Blood.

[348]  F. Balis,et al.  Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. , 1986, Pediatric hematology and oncology.

[349]  D. Collier,et al.  The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. , 1999, Pharmacogenetics.

[350]  M. Slovak,et al.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. , 2008, Blood.

[351]  D. Le Paslier,et al.  The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. , 1995, Blood.

[352]  W. Hofmann,et al.  Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations , 2012, Blood Cancer Journal.

[353]  J. Tjio,et al.  Chromosome preparations of bone marrow cells without prior in vitro culture or in vivo colchicine administration. , 1962, Stain technology.

[354]  J. Sierra,et al.  Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. , 2008, Blood.

[355]  C. Bloomfield,et al.  Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. , 2005, Blood.

[356]  G. Koren,et al.  Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. , 1990, The Journal of pediatrics.

[357]  M. Maris,et al.  Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia , 2011, Haematologica.

[358]  M. Levenstein,et al.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.

[359]  Ulrich Göbel,et al.  Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[360]  J. Ford,et al.  Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Imatinib (STI-571) , 2004, Leukemia & lymphoma.

[361]  Edward J. Lee,et al.  A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. , 1998, Blood.

[362]  E. Bruera,et al.  Difficulties in diagnosing neuropsychiatric complications of corticosteroids in advanced cancer patients: two case reports. , 2000, Journal of pain and symptom management.

[363]  S. Lawler,et al.  Prognostic implications of chromosomal findings in acute lymphoblastic leukaemia at diagnosis. , 1978, British medical journal.

[364]  M. Greaves,et al.  Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[365]  C. Bloomfield,et al.  Cytochemical profiles in acute lymphoblastic leukemia , 1979 .

[366]  H. Kantarjian,et al.  Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α , 2004 .

[367]  Huanhuan Sun,et al.  Survival improvement by decade of patients aged 0–14 years with acute lymphoblastic leukemia: a SEER analysis , 2014, Scientific Reports.

[368]  G. Janossy,et al.  The Ph1 Chromosome in Childhood Leukaemia , 1979, British journal of haematology.

[369]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[370]  H. Dombret,et al.  Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study , 2006, Leukemia.

[371]  A. Vora.  Management of osteonecrosis in children and young adults with acute lymphoblastic leukaemia , 2011, British journal of haematology.

[372]  K. Akashi,et al.  Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study) , 2013, Journal of Hematology & Oncology.

[373]  Martin C. Müller,et al.  Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. , 2009, Blood.

[374]  G. Lenz,et al.  Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL) , 2006 .

[375]  J. Lilleyman,et al.  Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. , 1996, Therapeutic drug monitoring.

[376]  M. Baccarani,et al.  Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. , 2002, Blood.

[377]  W. Hop,et al.  Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[378]  M. Tuncer,et al.  Acute lymphoblastic leukemia in fanconi's anemia , 1994, American journal of hematology.

[379]  S. Richards,et al.  Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials , 2007, Pediatric blood & cancer.

[380]  D. Hoelzer,et al.  Treatment of adult acute lymphoblastic leukemia. , 1999, Hematology. American Society of Hematology. Education Program.

[381]  M. Greaves,et al.  Blast Crisis of Chronic Myeloid Leukaemia (CML): I. PRESENTATION SIMULATING ACUTE LYMPHOID LEUKAEMIA (ALL) , 1976, British journal of haematology.

[382]  S. Rives,et al.  Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome‐positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL‐94, ALL‐99 and ALL‐2005 , 2011, British journal of haematology.

[383]  J. Downing,et al.  Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia , 2009, Nature Genetics.

[384]  M. Loh,et al.  Nelarabine May Be Safely Incorporated Into a Phase III Study for Newly Diagnosed T-Lineage Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group , 2010 .

[385]  W. Zuelzer,et al.  Long‐term cytogenetic studies in acute leukemia of children; The nature of relapse , 1976, American journal of hematology.

[386]  J. L. Goodman,et al.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.

[387]  K. Yamada,et al.  Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia , 2002, Bone Marrow Transplantation.

[388]  H. Dombret,et al.  Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial , 2007, Leukemia.

[389]  R. Larson,et al.  Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study , 2010, American journal of hematology.

[390]  B. Asselin,et al.  The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. , 1999, Advances in experimental medicine and biology.

[391]  L. Silverman,et al.  Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. , 2010, Blood.

[392]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[393]  C. Pui,et al.  A 50-year journey to cure childhood acute lymphoblastic leukemia. , 2013, Seminars in hematology.

[394]  J. Cayuela,et al.  First Results of the GRAAPH-2005 Study in younger Adult Patients with De Novo Philadelphia Positive Acute Lymphoblastic Leukemia , 2008 .

[395]  B. Cho,et al.  Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[396]  K. Kreuzer,et al.  Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. , 2012, Blood.

[397]  E. Thiel,et al.  Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. , 1995, Annals of internal medicine.

[398]  Robert Huether,et al.  The genomic landscape of hypodiploid acute lymphoblastic leukemia , 2013, Nature Genetics.

[399]  S. Armstrong,et al.  Targeting epigenetic programs in MLL-rearranged leukemias. , 2011, Hematology. American Society of Hematology. Education Program.

[400]  J. Oldenburg,et al.  Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). , 2007, Blood.

[401]  M. Patnaik,et al.  Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia , 2013, Blood Cancer Journal.

[402]  W. Crosby,et al.  Cytochemical identification of monocytes and granulocytes. , 1971, American journal of clinical pathology.